Publication date: Jul 17, 2024

Cirrhosis causes an imbalance in the coagulation pathway and leads to a tendency for both bleeding and clotting. SARS-CoV-2 has been reported to be associated with a hypercoagulable state. This study examines SARS-CoV-2’s impact on hemostasis in compensated patients with cirrhosis. We analyzed the US Collaborative Network, which comprises 63 HCOs in the U. S.A. Compensated cirrhosis patients were split into two groups: SARS-CoV-2-positive and -negative. Patients’ baseline characteristics were used in a 1:1 propensity score-matched module to create comparable cohorts. We compared the risk of portal vein thrombosis (PVT), deep venous thrombosis (DVT), and pulmonary embolism (PE) at 6 months, and 1 and 3 years. Of 330,521 patients, 27% tested positive and 73% remained negative. After PSM, both cohorts included 74,738 patients. Patients with SARS-CoV-2 had a higher rate of PVT compared to those without at 6 months (0. 63% vs 0. 5%, p < 0. 05), 1 year (0. 8% vs 0. 6%, p < 0. 05), and 3 years (1% vs. 0. 7%, p < 0. 05), a higher rate of DVT at 6 months (0. 8% vs. 0. 4%, p < 0. 05), 1 year (1% vs. 0. 5%, p < 0. 05), and 3 years (1. 4% vs. 0. 8%, p < 0. 05), and a higher rate of PE at 6 months (0. 6% vs. 0. 3%, p < 0. 05), 1 year (0. 7% vs. 0. 4%, p < 0. 05), and 3 years (1% vs. 0. 6%, p < 0. 05). The presence of SARS-CoV-2 infection in patients with compensated cirrhosis was associated with a higher rate of PVT, DVT, and PE at 6 months, and 1 and 3 years.

Open Access PDF

Semantics

Original Article